AiCure

Belkins
Everyone responds different to disease and treatment. We are working to understand how. Please visit our website to find out more and apply for our open positions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

news image

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

news image

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

news image

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

ENSYSCE, A CALIFORNIA BASED BIOTECH COMPANY WITH A MISSION TO SOLVE THE OPIOID CRISIS, EXPLORING A TREATMENT FOR COVID-19

TheDailyTimes | April 15, 2020

news image

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

Read More

CELL AND GENE THERAPY

Burixafor | November 09, 2020

news image

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More

PR Newswire | July 24, 2020

news image

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More

Biomica | October 13, 2020

news image

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

TheDailyTimes | April 15, 2020

news image

ENSYSCE, A CALIFORNIA BASED BIOTECH COMPANY WITH A MISSION TO SOLVE THE OPIOID CRISIS, EXPLORING A TREATMENT FOR COVID-19

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

Read More